Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 12

A Real-Life, International, Observational Study Demonstrating The Efficacy Of A Cosmetic Emulsion In The Supportive Care Of Mild-To-Moderate Facial Acne

Authors Bettoli V, Coutanceau C, Georgescu V

Received 16 February 2019

Accepted for publication 11 September 2019

Published 10 October 2019 Volume 2019:12 Pages 759—769

DOI https://doi.org/10.2147/CCID.S205170

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 3

Editor who approved publication: Dr Jeffrey Weinberg


Vincenzo Bettoli,1 Christine Coutanceau,2 Victor Georgescu2

1Department of Medical Sciences, Operational Unit of Dermatology, Azienda Ospedaliera – University of Ferrara, Ferrara, Italy; 2Laboratoires Dermatologiques AVENE, Pierre Fabre Dermo-Cosmétique, Lavaur, France

Correspondence: Christine Coutanceau
Laboratoires dermatologiques Avène, Pierre Fabre Dermo-Cosmétique, Les Cauquillous, Lavaur Cedex 81 506, France
Tel +33 5 6358 9652
Fax +33 5 6358 8667
Email christine.coutanceau@pierre-fabre.com

Purpose: Cosmetic emulsions are increasingly being used as supportive care products to alleviate the severe side effects and improve the clinical outcomes associated with conventional acne treatments. The objectives of this study were to determine, in a real-life setting, the global effectiveness of an emulsion with antiseborrheic, keratolytic and anti-Propionibacterium acnes activities as an adjunct to anti-acne therapy, and to evaluate the effect of the product on acne severity, noninflammatory and inflammatory lesions, hyperseborrhea, skin irritation and patient quality of life (QoL). Tolerance of the product was also assessed.
Patients and methods: This international observational study involved 3960 patients aged 12 years and over with mild-to-moderate acne. The conventional acne prescriptions for these patients were either initiated at inclusion or were reviewed. Reviewed prescriptions may have been left unchanged, switched, or an addition made to ongoing treatment. At inclusion, participants were instructed to apply the cosmetic product daily for 2–3 months in combination with their medical acne treatment.
Results: After 2 to 3 months of use, the combined therapy resulted in moderate-to-large improvements in acne in over 75% of the patients whose acne prescriptions were left unchanged (n=859). The combination treatment led to an improvement in acne severity (−38.3% change in the mean investigator’s global assessment score; p<0.0001) and QoL (−38.3% change in the mean Cardiff acne disability index score; p<0.0001), and reduced noninflammatory and superficial inflammatory lesions (−35.3% and −47.0%, respectively; p<0.0001), hyperseborrhoea (−40.6%; p<0.0001) and skin irritation (−37.2%; p<0.0001). Tolerance was very good.
Conclusion: Use of the cosmetic emulsion combined with conventional acne therapy significantly improved clinical outcomes and patient QoL, and was very well tolerated. The combined therapy may have improved patient satisfaction, leading to improved patient adherence and higher rates of therapeutic success.

Keywords: acne vulgaris, hyperseborrhoea, Propionibacterium acnes, acne treatment, supportive care, dermocosmetic product


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]